Loading
People with vague symptoms such as fatigue and weight loss are worked up with repeated scans. A multi-cancer blood test as the first step in Rapid Diagnostic Centres could point to which organ to examine first, or safely reassure; SYMPLIFY showed the Galleri test has high specificity in symptomatic patients.
People with vague symptoms such as fatigue and weight loss undergo repeated scans, so this idea makes a multi-cancer blood test the first step in Rapid Diagnostic Centre pathways, pointing to which organ to examine first or safely reassuring. SYMPLIFY from Oxford showed that Galleri, the GRAIL MCED, had high specificity and useful tissue-of-origin accuracy in symptomatic patients, and because cancer prevalence in symptomatic referrals is far higher than in screening, positive predictive value is better. An RCT would compare MCED-directed with standard work-up on time to diagnosis, imaging use and stage. The test is a 6,000-patient trial across ten NHS Rapid Diagnostic Centres. At early-clinical maturity it addresses the bottleneck The hardest cancers are found late.
Shares Early detection of cancer, Positive predictive value (PPV), The hardest cancers are found late.
Shares Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares GRAIL, Early detection of cancer, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, Galleri, Multi-cancer early detection (MCED), The hardest cancers are found late.
Shares Early detection of cancer, Galleri, Positive predictive value (PPV), Multi-cancer early detection (MCED).
Shares Early detection of cancer, The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late.
Shares Positive predictive value (PPV), Multi-cancer early detection (MCED), The hardest cancers are found late.